slide1
Download
Skip this Video
Download Presentation
Limitations in drug discovery

Loading in 2 Seconds...

play fullscreen
1 / 10

Limitations in drug discovery - PowerPoint PPT Presentation


  • 134 Views
  • Uploaded on

Limitations in drug discovery. More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-clinical models

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Limitations in drug discovery' - elijah


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Limitations in drug discovery

  • More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-clinical models
  • High failure rates indicate the limited ability of pre-clinical models to predict patient benefit in human populations.
slide2

Potential of Human genetics

to overcome limitations in drug discovery

  • Human genetics as “Experiment of nature” to prioritize molecular targets in drug discovery
      • => naturally occurring conditions (mutations)
      • that modulate (gain- or loss-of–function) a biological target (gene)
      • with reproducible effect (decreased or increased risk)
      • on human physiology (trait = appropriate proxy for drug efficacy)
    • -> mimic the effect of therapeutic modulation of a target
    • -> serve as estimate of dose-response curves (function-phenotype curves)
slide3

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

slide4

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

2

slide5

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

2

slide6

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

2

slide7

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

3. PCSK9LOFalleles: protect against CHD 2006

4.

2

3

slide8

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

3. PCSK9LOFalleles: protect against CHD 2006

4. PCSK9LOFalleles: no obvious adverse events 2006

2

3

4

slide9

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

3. PCSK9LOFalleles: protect against CHD 2006

4. PCSK9LOFalleles: no obvious adverse events 2006

high

PCSK9 GOF alleles

2

3

Risk of CHD

4

PCSK9 LOF alleles

low

low

high

LDL levels

slide10

PCSK9, LDL levels and coronary heart disease

1

1. PCSK9GOFalleles: increased LDL levels 2003

2. PCSK9LOFalleles: decreased LDL levels 2005-2006

3. PCSK9LOFalleles: protect against CHD 2006

4. PCSK9LOFalleles: no obvious adverse events 2006

5. Clinical trials: monoclonal antibody to PCSK9 2012

high

PCSK9 GOF alleles

2

3

Risk of CHD

4

PCSK9 LOF alleles

5

low

low

high

LDL levels

ad